Comparative Pharmacology
Head-to-head clinical analysis: BILDYOS versus STEGLATRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILDYOS versus STEGLATRO.
BILDYOS vs STEGLATRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BILDYOS (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to the ATP-binding pocket of FGFR kinases, inhibiting autophosphorylation and downstream signaling, thereby reducing proliferation and survival of tumor cells with FGFR alterations.
Steglatro (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
Adults: 20 mg orally once daily.
0.5 mg orally once daily for patients with type 2 diabetes; no dose adjustment for age, gender, or race.
None Documented
None Documented
Approximately 24 hours at steady state; supports once-daily dosing.
Terminal elimination half-life is approximately 12.4 hours in patients with type 2 diabetes, supporting once-daily dosing. No accumulation occurs at steady state.
Primarily biliary/fecal (unchanged drug and metabolites), approximately 90%; renal excretion accounts for less than 10% as unchanged drug and conjugates.
Approximately 65% of the dose is excreted in the urine as unchanged drug via active tubular secretion, and 35% is excreted in the feces as unchanged drug, indicating minimal metabolism.
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination Antidiabetic
SGLT2 Inhibitor